Novartis’ Expansion Of Menveo Further Set Back By “Complete Response”
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA issues “complete response” for an sBLA that would expand use of Novartis’ meningitis vaccine in children aged two months to 24 months, which could have offered a competitive advantage against Sanofi’s market-leading Menactra.